SG11201907242TA - IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF - Google Patents
IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOFInfo
- Publication number
- SG11201907242TA SG11201907242TA SG11201907242TA SG11201907242TA SG11201907242TA SG 11201907242T A SG11201907242T A SG 11201907242TA SG 11201907242T A SG11201907242T A SG 11201907242TA SG 11201907242T A SG11201907242T A SG 11201907242TA SG 11201907242T A SG11201907242T A SG 11201907242TA
- Authority
- SG
- Singapore
- Prior art keywords
- seoul
- international
- irtca
- daeryung
- eutilex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo milli woo 1111 X10111111 oimIE (10) International Publication Number WO 2018/146549 Al (2006.01) (2006.01) (2006.01) (51) International Patent Classification: C07K 16/30 (2006.01) A61P 35/04 C07K 7/06 (2006.01) A61P 35/02 A61K 39/395 (2006.01) A61P 37/02 A61K 38/17 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: (22) International Filing Date: PCT/IB2018/000201 Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/457,422 10 February 2017 (10.02.2017) US (71) Applicant: EUTILEX CO., LTD. [KR/KR]; Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). (72) Inventors: KWON, Byoung, S.; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1- ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Seoung- joo; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Techno- town 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Joong, Won; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Seunghyun; c/o Eutilex Co., Ltd, Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). (74) Agent: CHANG, Duck Soon; Kim & Chang, Seyang B/D, 39 Sajikno-8-gil, Jongno-gu, Seoul 03170 (KR). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: IFN-y-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF 00 (57) : Provided are IFN-y-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding O fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T 0 cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762457422P | 2017-02-10 | 2017-02-10 | |
PCT/IB2018/000201 WO2018146549A1 (en) | 2017-02-10 | 2018-02-09 | IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907242TA true SG11201907242TA (en) | 2019-09-27 |
Family
ID=63108020
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907242TA SG11201907242TA (en) | 2017-02-10 | 2018-02-09 | IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF |
SG10201914115RA SG10201914115RA (en) | 2017-02-10 | 2018-02-09 | IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914115RA SG10201914115RA (en) | 2017-02-10 | 2018-02-09 | IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF |
Country Status (11)
Country | Link |
---|---|
US (3) | US10919976B2 (en) |
EP (2) | EP3882271A3 (en) |
JP (1) | JP2020508636A (en) |
KR (1) | KR20190117467A (en) |
CN (1) | CN109689691A (en) |
AU (1) | AU2018218324A1 (en) |
BR (1) | BR112019016513A2 (en) |
CA (1) | CA3052740A1 (en) |
MX (1) | MX2019009619A (en) |
SG (2) | SG11201907242TA (en) |
WO (1) | WO2018146549A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101566539B1 (en) | 2012-06-08 | 2015-11-05 | 국립암센터 | Novel epitope for switching to Th2 cell and use thereof |
EP3882271A3 (en) | 2017-02-10 | 2022-01-05 | Eutilex Co., Ltd. | Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3321157A1 (en) | 1983-06-11 | 1984-12-13 | Bayer Ag, 5090 Leverkusen | METHOD FOR PRODUCING 1H-PYRROL-2,5-DIONES |
DE68928427T2 (en) | 1988-09-15 | 1998-06-04 | Univ Columbia | Modified carbohydrate antibodies and method of manufacture and use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
WO1998034957A1 (en) | 1997-02-11 | 1998-08-13 | Immunomedics, Inc. | STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE |
PT1071700E (en) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO2000058362A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
ES2571230T3 (en) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedure to control the activity of an immunofunctional molecule |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
JP4668498B2 (en) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | Method for producing polypeptide |
CN102311986B (en) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | Produce the cell of antibody compositions |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP1333032A4 (en) | 2000-10-06 | 2005-03-16 | Kyowa Hakko Kogyo Kk | Method of purifying antibody |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
MXPA06014075A (en) | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof. |
DK2343320T3 (en) | 2005-03-25 | 2018-01-29 | Gitr Inc | ANTI-GITR ANTIBODIES AND APPLICATIONS THEREOF |
JP2008278814A (en) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | Release of immunoregulation by agonistic anti-human gitr antibody, and application thereof |
LT3023438T (en) * | 2009-09-03 | 2020-05-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
KR101566539B1 (en) * | 2012-06-08 | 2015-11-05 | 국립암센터 | Novel epitope for switching to Th2 cell and use thereof |
US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
KR102433464B1 (en) * | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | Anti-gitr antibodies and methods of use thereof |
SG10201810507WA (en) * | 2014-06-06 | 2018-12-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
MA41044A (en) * | 2014-10-08 | 2017-08-15 | Novartis Ag | COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT |
EP3882271A3 (en) | 2017-02-10 | 2022-01-05 | Eutilex Co., Ltd. | Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof |
-
2018
- 2018-02-09 EP EP21152568.8A patent/EP3882271A3/en not_active Withdrawn
- 2018-02-09 JP JP2018569136A patent/JP2020508636A/en active Pending
- 2018-02-09 CA CA3052740A patent/CA3052740A1/en active Pending
- 2018-02-09 MX MX2019009619A patent/MX2019009619A/en unknown
- 2018-02-09 BR BR112019016513A patent/BR112019016513A2/en not_active Application Discontinuation
- 2018-02-09 KR KR1020197001731A patent/KR20190117467A/en not_active Application Discontinuation
- 2018-02-09 CN CN201880003066.2A patent/CN109689691A/en active Pending
- 2018-02-09 SG SG11201907242TA patent/SG11201907242TA/en unknown
- 2018-02-09 WO PCT/IB2018/000201 patent/WO2018146549A1/en unknown
- 2018-02-09 SG SG10201914115RA patent/SG10201914115RA/en unknown
- 2018-02-09 EP EP18751349.4A patent/EP3472209A4/en not_active Withdrawn
- 2018-02-09 AU AU2018218324A patent/AU2018218324A1/en active Pending
-
2019
- 2019-01-03 US US16/239,398 patent/US10919976B2/en active Active
- 2019-01-23 US US16/255,690 patent/US10626183B2/en active Active
-
2021
- 2021-02-05 US US17/169,091 patent/US20210277139A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020508636A (en) | 2020-03-26 |
EP3472209A4 (en) | 2020-07-29 |
US20210277139A1 (en) | 2021-09-09 |
US20190330358A1 (en) | 2019-10-31 |
EP3472209A1 (en) | 2019-04-24 |
US20190233535A1 (en) | 2019-08-01 |
EP3882271A2 (en) | 2021-09-22 |
US10919976B2 (en) | 2021-02-16 |
BR112019016513A2 (en) | 2020-04-07 |
MX2019009619A (en) | 2019-12-18 |
CN109689691A (en) | 2019-04-26 |
AU2018218324A1 (en) | 2019-08-22 |
SG10201914115RA (en) | 2020-02-27 |
WO2018146549A1 (en) | 2018-08-16 |
EP3882271A3 (en) | 2022-01-05 |
US10626183B2 (en) | 2020-04-21 |
CA3052740A1 (en) | 2018-08-16 |
KR20190117467A (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201804127SA (en) | Ctla4 binders | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201805579SA (en) | Recombinant igg fc multimers | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
SG11201808994YA (en) | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof | |
SG11201903693QA (en) | Polypeptide variants and uses thereof | |
SG11201906961UA (en) | Polypeptide variants and uses thereof |